NEW YORK and MELBOURNE, Australia, April 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing new ...
An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial
As of 3 March 2024, there have been 774,834,251 confirmed cases of COVID-19 with 7,037,007 deaths 1. Vaccines designed for SARS-CoV-2 have been effective in mitigating the COVID-19 pandemic 2. Various ...
Fully enrolled, randomized, double-blind, sham-controlled Phase 2 study has completed treatment administration in 99 patients; Company continues ...
LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function (ADCS-ADL23) In pre-specified subgroups of patients with moderate Alzheimer’s ...
A phase 2 study using metronomic gemcitabine, doxorubicin, and docetaxel plus nivolumab in advanced leiomyosarcoma and liposarcoma (NCT04535713). The broad-spectrum KIT inhibitor NB003 and activity in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results